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Abstract
Viral hepatitis is a leading cause of morbidity and mortality worldwide, but has long 
been neglected by national and international policymakers. Recent modelling stud‐
ies suggest that investing in the global elimination of viral hepatitis is feasible and 
cost‐effective. In 2016, all 194 member states of the World Health Organization en‐
dorsed the goal to eliminate viral hepatitis as a public health threat by 2030, but 
complex systemic and social realities hamper implementation efforts. This paper 
presents eight case studies from a diverse range of countries that have invested in 
responses to viral hepatitis and adopted innovative approaches to tackle their re‐
spective epidemics. Based on an investment framework developed to build a global 
investment case for the elimination of viral hepatitis by 2030, national activities and 
key enablers are highlighted that showcase the feasibility and impact of concerted 
hepatitis responses across a range of settings, with different levels of available re‐
sources and infrastructural development. These case studies demonstrate the util‐
ity of taking a multipronged, public health approach to: (a) evidence‐gathering and 
planning; (b) implementation; and (c) integration of viral hepatitis services into the 
Agenda for Sustainable Development. They provide models for planning, investment 
and implementation strategies for other countries facing similar challenges and re‐
source constraints.
K E Y W O R D S
developing countries, disease elimination, hepatitis B, hepatitis C, investment case, 
organizational case studies
1  | INTRODUC TION
Viral hepatitis contributes substantially to the global burden of dis‐
ease, with 248 million people infected with hepatitis B and 71 million 
infected with hepatitis C worldwide.1 If left untreated, chronic viral 
hepatitis can cause life‐threatening complications, such as cirrhosis 
and hepatocellular carcinoma.2 Despite this, the public health con‐
sequences of viral hepatitis have long been neglected.1 In contrast 
to the progress in combating many other communicable diseases in 
recent years, viral hepatitis‐related morbidity and mortality continue 
to rise.1,3 In 2010 viral hepatitis was the 10th leading cause of death, 
but by 2015, with 1.2 million deaths, it had overtaken HIV, malaria and 
tuberculosis to rise to sixth.4 Most viral hepatitis deaths are avertable 
through increased access to prevention, diagnosis and treatment.
In areas of high hepatitis B endemicity (eg Southeast Asia 
and sub‐Saharan Africa), perinatal mother‐to‐child transmission 
(MTCT) and horizontal transmission during childhood are the most 
common routes of infection, while sexual contacts, unsafe inject‐
ing practices, and unhygienic medical or cosmetic procedures 
Key points
• Viral hepatitis is the 6th leading cause of death globally, 
surpassing all other chronic infectious diseases including 
HIV, tuberculosis and malaria
• Elimination of viral hepatitis as a public health threat is 
achievable; all WHO member countries endorsed this 
goal formally in 2016
• Planning, implementation and integration of national 
responses to viral hepatitis is ongoing, and many coun‐
tries have adopted innovative approaches to address 
the diverse challenges of this endeavour in their local 
contexts
• Existing approaches demonstrate that investing in viral 
hepatitis is affordable and cost‐effective, provides mul‐
tisectoral cost‐benefits, and alleviates the human bur‐
den of the epidemic
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drive transmission elsewhere.5‐7 Risk of developing chronic hep‐
atitis B infection is inversely related to age at infection: around 
90% of infants infected perinatally develop chronic infection, un‐
less vaccinated at birth. This risk decreases to around 30% among 
children infected before the age of six years and to less than 5% of 
persons infected as adults.8‐10
The hepatitis C epidemic is similarly geographically diverse and 
mode of transmission differs substantially between regions.11‐14 
Globally, an estimated 52% of people who inject drugs (PWID) are 
hepatitis C antibody positive.15 Lack of access to needle and syringe 
programmes (NSPs) and opioid antagonist treatment (OAT) result in 
unsafe injecting practices, which are the major route of transmission 
in high‐income countries.15,16 In low‐ and middle‐income countries, 
additional transmission occurs in healthcare settings through sub‐
standard infection control practices.17
In 2016, the 69th World Health Assembly adopted the Global 
Health Sector Strategy on Viral Hepatitis (GHSSH) 2016‐2021. The 
strategy outlines five synergistic prevention and treatment service 
coverage targets to achieve the elimination of viral hepatitis as a 
public health threat by 2030 (defined as 90% reduction in incidence 
and 65% in mortality, see Table 1).18 Implementation of the strategy 
is expected to strengthen health systems while enabling progress 
toward the United Nations' Sustainable Development Goal (SDG) 3 
target of universal health coverage.19,20 Modelling studies suggest 
that rapid investment in diagnostic, prevention, and treatment ser‐
vices could achieve the World Health Organization (WHO) targets 
by 2030.21,22
1.1 | How can viral hepatitis be eliminated by 2030?
Eliminating viral hepatitis requires substantial investments in health 
systems strengthening and the full continuum of hepatitis ser‐
vices.18 Investing in the prevention and treatment of viral hepatitis 
provides many direct, indirect and cross‐sectoral economic benefits 
through saving lives and alleviating the cost burden of disease to the 
individual, their families and the state.23‐26 To achieve elimination 
at a national level, the country‐specific context and its unique chal‐
lenges must be considered. A multipronged approach comprising 
three main pillars is most effective in addressing the local context; 
comprising (a) evidence‐gathering and planning the response; (b) im‐
plementation of disease‐specific activities, including investments in 
the delivery of care; and (c) integration of the viral hepatitis response 
into SDG 3 by adopting a public health approach and embedding ser‐
vices into universal health coverage.27
The necessary tools for viral hepatitis elimination are already 
available, but worldwide implementation of a concerted viral hepa‐
titis response is slow and faces many challenges. These include low 
levels of investments in health overall; inadequate data and weak 
surveillance systems; poor infrastructure; low awareness among 
policymakers, at‐risk populations and primary care practitioners; 
high prices of some diagnostics and treatments; and a lack of prior‐
itisation of viral hepatitis.28,29 While most countries are on track to 
meet the WHO's 2030 target of < 0.1% Hepatitis B surface antigen 
(HBsAg) prevalence among 5‐year‐olds, without substantial further 
investments this target is currently unachievable for 20 countries, 
mainly in Africa and the Western Pacific. Moreover, only 12 coun‐
tries are currently on track to achieve the hepatitis C elimination goal 
that all WHO member states adopted in 2016.30
We have developed a Viral Hepatitis Investment Framework 
outlining the resourcing required to achieve elimination, the cost 
of the elimination of viral hepatitis globally, and methods for coun‐
tries to address existing challenges.31 The Viral Hepatitis Investment 
Framework highlights key enablers to support a comprehensive 
viral hepatitis response and outlines priority national and interna‐
tional activities to maximise return on investment (Figure 1). Using 
the structure of the Investment Framework, this paper presents 
case studies from diverse countries (Table 2) that are successfully 
implementing innovative strategies to eliminate viral hepatitis (see 
Table 3). Additional case studies listed in Table 3 are summarised in 
the Appendix S1 (Figures 2‐4).
1.2 | Evidence‐gathering and planning
Low‐quality surveillance systems and a lack of reliable cause‐spe‐
cific mortality data limit countries' capacity to guide, implement and 
monitor effective viral hepatitis responses.32,33 To advocate for an 
adequate allocation of domestic resources and to mobilise external 
funding support, countries should develop a national plan that sets 
ambitious but achievable targets, informed by a robust local invest‐
ment case for viral hepatitis. Gathering accurate data to inform a 
targeted approach can improve the cost‐effectiveness of specific 
interventions.34‐36 Since the launch of the GHSSH 2016‐2021, more 
countries have developed national hepatitis plans1 and both local 
and global investment cases for the elimination of viral hepatitis 
have been built.31,35,37 Many countries have begun collecting epide‐
miological data through national seroprevalence surveys or by add‐
ing key hepatitis indicators into existing surveillance systems. Below, 
we give examples of countries that have gathered evidence and are 
developing a national plan (Georgia), produced an investment case 
for elimination (South Africa) and obtained accurate data to inform 
the response (Scotland).
1.3 | Georgia: the development of a national plan
Georgia was the first country in the WHO European region to set 
a hepatitis C elimination goal and develop a national plan for viral 
hepatitis tailored to the local context. Georgia's significant experi‐
ence with HIV prevention and control programmes and the exist‐
ing human and technical capacities to implement large‐scale health 
programmes facilitated the implementation of their national hepati‐
tis C elimination programme.38 An international Technical Advisory 
Group assisted with describing the local hepatitis C epidemiology 
and proposing strategies, objectives and actions to address gaps in 
advocacy and awareness, surveillance, harm reduction, blood safety, 
infection control, and evidence‐based screening and linkage to care. 
Gilead Science provided direct‐acting antiviral (DAA) w to Georgia at 
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no cost after the elimination programme commenced; reportedly, a 
key reason for their decision was the Georgian Government's com‐
mitment to an elimination response.
The programme initially focused on increasing access to afford‐
able diagnostics; providing free DAA treatment to persons with severe 
liver disease at highest‐risk of hepatitis C‐related mortality; and build‐
ing capacity to achieve programme goals of preventing transmission 
and eliminating the disease.39 Initial obstacles included suboptimal 
alignment of programme development and implementation, leading 
to bottlenecks in patient flow and wait lists.40 Training for healthcare 
workers was only provided after the programme launched; however, 
doctors have subsequently received continuous technical support.
The programme has now expanded its scope to treat every per‐
son chronically infected with hepatitis C, as outlined in the “Strategic 
plan for the Elimination of Hepatitis C Virus in Georgia, 2016‐2020”. 
Hepatitis C treatment services are provided at treatment centres 
located throughout the country and treatment decentralisation in 
harm reduction centres and primary care is ongoing. Patient out‐of‐
pocket fees for diagnostics and clinical monitoring are based on abil‐
ity to pay. Georgia is working to integrate its hepatitis C elimination 
programme into the overall health system, because this will benefit 
the management of other health problems such as HIV and tubercu‐
losis.41 This is primarily being achieved via treatment decentralisa‐
tion into primary care and harm reduction services.
The implementation of the national action plan increased 
access to hepatitis C testing and linkage to care while driving 
improvements in monitoring and surveillance, infection control 
and prevention.38,41 The evaluation of harm reduction‐based 
peer‐supported hepatitis C treatment demonstrated excellent 
treatment uptake and retention in care among PWID based in 
Tbilisi.42 By January 2019, 53 000 people had initiated treatment 
with the new DAAs, of whom almost 34 800 had already achieved 
hepatitis C cure (Figure 5A). Remaining challenges relate to the 
marginalised status of PWID, with stigma and discrimination 
preventing PWID from accessing hepatitis C services. Punitive 
drug laws (such as criminal responsibility for personal drug use) 
challenge the effectiveness of harm reduction programmes and 
lead to high rates of incarceration and hepatitis C transmission 
in prisons, where access to OST is limited. As well, as in other 
countries aiming for hepatitis C elimination, treatment numbers 
declined after the first two years of the programme, with many 
people being unaware of their hepatitis C status or not com‐
mencing treatment.
1.4 | South Africa: The development of an 
investment case
South Africa's National Action Plan 2017‐2021 is one of the first 
examples of an investment case that combines tools for costing, 
impact modelling, cost‐effectiveness analysis, and fiscal space 
analysis for scaled‐up hepatitis B and hepatitis C disease control 
scenarios.35 The action plan was developed in collaboration with 
leading South African experts, Ministry of Health officials, and 
external specialists in global health policy and economics, who 
TA B L E  1   Viral hepatitis service coverage and impact targets
Target area Baseline 2015 2020 Target 2030 Target
Service coverage targets
Hepatitis B virus vaccination: childhood 
 vaccine coverage (third dose coverage)
82% of infants 90% 90%
Prevention of hepatitis B virus mother‐to‐child 
transmission: hepatitis B virus birth‐dose 
coverage or other approach to prevent 
mother‐to‐child transmission
38% 50% 90%
Blood safety: donations screened with quality 
assurance
89% 95% 100%
Injection safety: use of engineered devices 5% 50% 90%
Sterile needle/syringe set distributed per 
 person per year for people who inject drugs
20 200 300
Viral hepatitis B and C diagnosis (coverage %) <5% of chronic hepatitis infections diagnosed 30% 90%
Viral hepatitis B and C treatment (coverage %) <1% receiving treatment 3 million 80% eligible treated
Impact targets
Incidence: new cases of viral hepatitis B and 
C infections
Between 6 and 10 million infections are 
reduced to 0.9 million infections by 2030 
(95% declined in hepatitis B virus infections, 
80% decline in hepatitis C virus infections)
30% reduction 
(equivalent to 1% 
prevalence of HBsAg 
among children)
90% reduction 
(equivalent to 0.1% 
prevalence of HBsAg 
among children)
Mortality: viral hepatitis B and C deaths 1.4 million deaths reduced to less than 
500 000 by 2030 (65% for both viral hepa‐
titis B and C)
10% reduction 65% reduction
Source: Global Health Sector Strategy on Viral Hepatitis, 2016‐2021.18
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assessed cost and affordability, health impact and cost‐effective‐
ness for four priority interventions: hepatitis B birth dose vaccina‐
tion, prevention of MTCT and treatment for hepatitis B and C.
The model suggests expanded hepatitis B prevention and treat‐
ment for hepatitis B and C (using DAAs for the latter) is cost‐effective 
and affordable in the South African context,35 noting that hepatitis B 
F I G U R E  1   Investment framework for 
viral hepatitis elimination
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birth dose vaccination should be prioritised if funds are insufficient 
for the full implementation. The five‐year Action Plan was estimated 
to cost US$270 million, with the “testing, care, and treatment” com‐
ponent being the most costly. Whilst this is a significant amount of 
money, seen against 5‐year HIV expenditure, the cost of the Hepatitis 
Action Plan is estimated to be less than 4% of the projected HIV 
spend in South Africa.43 Integrating the action plan into the existing 
health system, particularly maternal and child health and HIV/AIDS 
services, was estimated to improve implementation feasibility.
The modelling data suggest the initial five‐year investment could 
avert an estimated 13 000 hepatitis B‐related deaths and 7000 
hepatitis C‐related deaths. Moreover, a continued expansion of 
the treatment programme beyond 2021 has the potential to avert 
672 000 hepatitis B‐infections and 60 000 deaths averted from hep‐
atitis C‐related liver disease, which would put South Africa firmly on 
the path to achieve elimination by 2030 (Figure 5B).35
The multi‐stakeholder approach used to develop an investment 
case for the cost‐effectiveness and affordability of hepatitis con‐
trol and elimination for South Africa provides a template for other 
countries.44 Implementation of the investment case‐informed Viral 
Hepatitis Action Plan is expected to commence on 1st April 2019, with 
five priority interventions during the first year: (a) hepatitis B birth 
dose vaccination; (b) healthcare worker hepatitis screening, vaccina‐
tion and training in viral hepatitis (c) increasing awareness, diagnosis 
and management of Hepatitis B virus (Tenofovir is on the Essential 
Medicine list); (d) registration of DAAs and price negotiations; (e) a 
comprehensive package of viral hepatitis services for key populations 
– men who have sex with men and people who use/inject drugs.
Key obstacles to the response are a lack of funding being al‐
located to the Programme due to fiscal constraints; a shortage of 
trained health workers; lack of knowledge about viral hepatitis in 
the general public; viral hepatitis‐related stigma; limited access to 
harm reduction services; and punitive drug laws. There is a need to 
improve viral hepatitis services in other key populations, including 
prisoners, sex workers and men who have sex with men. Moreover, 
DAAs are yet to be registered in South Africa due to administrative 
delays at the South African Health Products Regulatory Authority, 
preventing broader hepatitis C treatment scale‐up.
In order to address these obstacles, the South African Viral 
Hepatitis Working Group has established three subcommittees 
to oversee implementation of the hepatitis B birth dose vaccine, 
training of healthcare workers in conjunction with training on 
new HIV treatment regimens, and hepatitis C micro‐elimination 
programmes.
1.5 | Scotland: accurate data to inform the response
In Scotland, advocates used political pressure and scientific evi‐
dence to raise awareness of the human impact of hepatitis C and its 
links to inequalities, which generated political consensus to support 
significant funding and evidence‐based policy initiatives.45 Social 
and political recognition of the scale of the problem galvanised poli‐
cymakers into action. Innovative strategies such as the introduction T
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of dried blood spot (DBS) sampling in community drug services 
made the model of viral hepatitis care more acceptable to affected 
communities and helped overcome barriers to testing.46 Adopting a 
project management approach ensured achievable goal‐setting and 
controlled ongoing cost. Substantial investment in a robust moni‐
toring and surveillance system – combined with ambitious treat‐
ment targets – facilitated progress and demonstrated immediate 
impact, which helped to sustain momentum.47 Scotland's response 
– the National Hepatitis C Action Plan – has been a phased one. 
Launched in 2006, Phase I focused on gathering evidence to inform 
and generate proposals for the development of hepatitis C services 
and identify the additional investment required. Subsequently, in 
Phase II the Scottish Government committed funds to substantially 
improve prevention (including increasing coverage of harm reduc‐
tion services), diagnosis and treatment services and deliver evi‐
dence‐based actions throughout the country for improved hepatitis 
C prevention and control (Figure 5C). Since 2011, the Hepatitis C 
Action Plan has been integrated with other national policies within 
the Scottish Government's Framework on Sexual Health and Blood 
Borne Viruses, which adopts a multi‐agency outcomes‐based ap‐
proach with a strong focus on challenging inequalities.48,49
The national strategy to improve prevention, diagnosis and treat‐
ment services led to a significant decline in hepatitis C incidence, 
more new diagnoses, more people undergoing hepatitis C treat‐
ment and achieving cure, reductions in liver‐related morbidity and 
mortality, and a decreased population prevalence of chronic hepa‐
titis C.47,50‐52 Scotland's example showcases the utility of evidence‐
based national hepatitis C strategies in reducing the financial and 
societal burden of the epidemic52,53 and provides a working model 
for other countries to follow.
Despite the progress made in improving harm reduction ser‐
vices in Scotland during the era of interferon‐based treatment, the 
prevalence of hepatitis C infection had remained stubbornly high. 
The recent scale‐up of DAA therapy to PWID is hoped to bring a 
treatment‐as‐prevention benefit.54 While the roll‐out of DBS test‐
ing was effective at diagnosing infection, a substantial minority of 
the infected population remains undiagnosed. It has proven difficult 
to fully engage general practitioners in case‐finding initiatives, with 
awareness‐raising campaigns having limited success.55,56 However, 
it is hoped that the availability of DAAs within primary care and 
other community settings will increase treatment uptake as the util‐
ity of the new therapies is recognised.
TA B L E  3   National activities and country examples aimed at elimination of viral hepatitis
 National activities Country examples presented in this paper
Evidence‐gathering and 
planning
National hepatitis plan (addressing hepa‐
titis B, hepatitis C or both)
Georgia, Australia, Brazil, China, Egypt, Iceland, Malaysia, Portugal, 
Scotland, South Africa
Accurate data to inform the response 
(Surveillance and Monitoring)
Scotland, Portugal, Brazil, Egypt, Georgia, Iceland, Pakistan, South Africa
Local investment case South Africa, Rwanda
Implementation Raising awareness and stigma reduction Brazil, Australia,, China, Egypt, Iceland, Malaysia, Portugal, Pakistan
Investment in prevention China, Fiji, Pakistan, Australia, Brazil, Iceland, Georgia, Malaysia, Portugal, 
Scotland
Testing, linkage to care and treatment Egypt, Australia, China, Georgia, Iceland, Malaysia, Portugal, Scotland, 
South Africa
Integration Investment and financing for 
sustainability
Australia, China, Iceland, Malaysia, Rwanda
Health Systems Strengthening Rwanda, Brazil, Fiji, Georgia, Malaysia, South Africa
Source: Global Policy Report on the prevention and control of viral hepatitis.106
F I G U R E  2   Timeline of national activities, Portugal
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1.6 | Implementation
Globally, nine of the 10 people living with viral hepatitis are una‐
ware of their infection,33 and lack of public knowledge is often 
compounded by viral hepatitis‐related stigma and discrimination. 
Implementation of a viral hepatitis strategy should therefore include 
awareness‐raising activities to generate demand for viral hepati‐
tis care (eg through social media campaigns, such as in Brazil57) in 
conjunction with supportive laws, policy and guidelines that aim to 
reduce stigma and enable the establishment of community‐focused 
responses.46
Prevention activities should be implemented and scaled up to 
effectively eliminate viral hepatitis transmission. A highly effec‐
tive hepatitis B vaccine has been available since the 1980s, and 
early immunisation plus the distribution of hepatitis B immuno‐
globulin (HBIg) to at‐risk infants prevents perinatal transmission, 
as China has demonstrated.58 Harm reduction interventions, in‐
cluding NSPs and provision of OAT, cost‐effectively reduce pri‐
mary and reinfection incidence among PWID.59‐61 Iatrogenic 
transmission can be eliminated through routine screening of blood 
supply62 and implementation of safe infection practices (including 
reducing unnecessary injections, staff training and effective waste 
management),63 while simultaneously contributing to health sys‐
tems strengthening.4,64
Finally, implementation of a viral hepatitis response must aim to 
optimise the viral hepatitis care cascade by substantially improving 
testing rates, linkage to care and treatment numbers. The case of 
Egypt (and Iceland, see Appendix S1) demonstrates that concerted 
F I G U R E  3   Timeline of national activities, Pakistan (A), Fiji (B), and Iceland (C)
(A)
(B)
(C)
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efforts enable substantial advances towards the WHO targets of 
90% of people diagnosed and 80% of eligible people treated.30,65,66
Below are examples of implementation: raising awareness and 
stigma reduction (Brazil), investment in prevention (China), and in‐
vestment in testing, linkage to care and treatment (Egypt).
1.7 | Brazil: raising awareness and stigma reduction
Brazil, a middle‐income country, has been providing universal access 
to antiretroviral therapy for HIV since 1996, driven by strong politi‐
cal will, multisectoral mobilisation and use of Trade Related Aspects 
of Intellectual Property Rights (TRIPS) flexibilities, and civil society 
engagement.67 It has championed the cause of viral hepatitis and ad‐
vocated for an intensified global response for many years. Learning 
from its successes in reversing the trend of the HIV epidemic, Brazil 
established a national hepatitis programme informed by up‐to‐date 
estimates of disease prevalence, international guidelines and cost‐ef‐
fectiveness in the Brazilian Unified Health System.57 Brazil invested 
in universal hepatitis B vaccination, increased capacity for hepati‐
tis C testing in HIV services, expanded its laboratory network and 
set up a referral system for hepatitis patients. To reach the target 
population, the Ministry of Health conducted new public awareness 
and diagnosis campaigns using a variety of media with endorsement 
from civil society and the scientific community.57
Brazil was able to obtain an unprecedented discount for an 
upper‐middle‐income country through price negotiations with orig‐
inator pharmaceutical companies. Between 2015 and 2018 it pro‐
vided treatment to nearly 90 000 people, and is expected to treat 
another 50 000 patients in 2019, largely thanks to the strong advo‐
cacy of civil society.
The remarkable process applied in Brazil was based on epidemi‐
ological data and scientific evidence, and motivated by its engage‐
ment with the SDGs, which may inspire other countries to identify 
ways to achieve these goals by 2030.57 Brazil has pledged to pro‐
vide free hepatitis C treatment to everyone infected and is one of 
12 countries on track to achieve hepatitis C elimination by 2030 
(Figure 6A).30
Despite this progress, geographical, social and economic dis‐
parities in Brazil challenge the provision of equitable service access 
across varied geographical regions. Brazil is working to improve di‐
agnosis rates and mitigate losses to follow‐up, resulting from the 
long delays between diagnosis and treatment initiation arising from 
small numbers of specialists who can provide DAA treatment.68
1.8 | China: investment in prevention
China is home to nearly one third of all people living with hepatitis B 
infection globally. HBsAg prevalence is estimated at 5.5%2 and hepa‐
titis B causes over 300 000 deaths annually due to liver diseases.69 
The implementation of a universal hepatitis B vaccination programme 
for infants has reduced chronic hepatitis B incidence dramatically dur‐
ing the past two decades. The full implementation of a national pro‐
gramme for the prevention of MTCT guarantees adequate supply of 
HBIg for at‐risk newborns. Domestic procurement of the hepatitis B 
vaccine and auto‐disable syringes ensures sustainable supply chains 
and stimulates regional industry and technology markets.70
Driven by strong political commitment and with support from 
the Global Alliance on Vaccine and Immunization, including an in‐
vestment of ~ USD76 million to subsidise the hepatitis B catch‐up 
vaccination programme for 15 million children through public‐pri‐
vate partnerships such as with Rotary and the ZeShan Foundation,71 
multiple strategies were developed and implemented collabora‐
tively (Figure 6B). As a result, >95% of infants receive the hepati‐
tis B vaccine within 24 hours of birth.72‐75 This programme led to 
a nationwide catch‐up vaccination drive for children up to the age 
of 15, reaching 68 million people over a 3‐year period (2008‐2011) 
(private communication). Between 1992 and 2013, China's efforts 
have prevented 90 million cases of chronic hepatitis B infection and 
24 million fewer people are carriers of the virus –a massive reduction 
in the global burden of viral hepatitis.70
Although China has made considerable progress with hepatitis B, 
systemic obstacles to the elimination of MTCT remain. The physician‐
centred approach of the medical service infrastructure discourages 
affected pregnant women from seeking timely treatment, because 
F I G U R E  4   Timeline of national activities, Malaysia
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physicians trained to provide treatment (ie obstetricians, gynaecolo‐
gists, gastroenterologists and infectious disease specialists working in 
central hospitals) are often reluctant to do so. Moreover, China is yet to 
implement a comprehensive national strategy addressing its hepatitis C 
epidemic. Few DAAs have been approved and their high cost restricts 
inclusion in basic health insurance programmes; consequently, DAA 
treatment is not universally available. Policy changes and education 
campaigns are needed to overcome stigma and discrimination and im‐
prove diagnosis rates, and linkage to care needs improvement.
1.9 | Egypt: testing, linkage to care and treatment
Egypt has a very high burden of hepatitis C infection and disease, with 
approximately 7% of Egyptians aged 18‐59 living with chronic hepatitis 
F I G U R E  5   Timeline of national activities, Georgia (A), South Africa (B), and Scotland (C)
(A)
(B)
(C)
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C infection in 2015.76 This large reservoir of active infection and con‐
tinued unsafe medical practices contribute to ongoing transmission; in 
2016, an estimated 150 000 Egyptians were newly infected.77
Egypt is committed to ending its generalised hepatitis C epi‐
demic. It has developed one of the largest national programmes 
for hepatitis C treatment.78 Egypt provides free and universal 
access to locally produced DAA treatment, as part of a national 
action plan for the prevention and control of viral hepatitis. To 
maximise efficiencies, the country has rolled out mass screening 
since October 2018, providing direct linkage to hepatitis C care. 
Over six months, more than 49 million people were reached, of 
whom over 2 million were diagnosed as hepatitis C‐antibody pos‐
itive (in addition, >2.5 million possible cases of diabetes and > 10 
million possible cases of hypertension were identified and referred 
for further assessment and management). Of hepatitis C patients 
linked to care and confirmed as ribonucleic acid (RNA) positive, 
750 000 started treatment.
By 2019, over 2.4 million Egyptians had been treated, and the 
country is on track to achieve WHO elimination targets in spite of its 
high hepatitis C prevalence (Figure 6C).78,79 Egypt's response was fa‐
cilitated by strong political will and government advocacy, effective 
price negotiations, removal of patent barriers on DAAs and ability to 
produce DAAs locally.66,80
Despite great progress Egypt's response is challenged by diffi‐
culties in capturing non‐responders to treatment and lack of appro‐
priate medications to initiate retreatment. Moreover, children under 
12 years old cannot be treated because the medications have not 
yet been approved for this age group. Finally, plans and strategies 
for surveillance to reliably capture whether hepatitis C elimination 
targets have been met are not fully developed.
F I G U R E  6   Timeline of national activities, Brazil (A), China (B), and Egypt (C)
(A)
(B)
(C)
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1.10 | Integration
The cost burden of viral hepatitis diagnostic tests and treatment – 
in particular the new DAA treatment for hepatitis C – challenges 
the feasibility and sustainability of effective viral hepatitis elimina‐
tion activities. Unlike for other major communicable diseases such 
as HIV, tuberculosis and malaria, there is little funding available 
for viral hepatitis at an international level and most countries lack 
dedicated hepatitis budgets or programmes.18 Although the pri‐
vate sector (such as pharmaceutical companies) and international 
funders and organisations are important actors in global elimination 
efforts, most funding will have to be mobilised from public, domestic 
sources to ensure the sustainability of viral hepatitis services as part 
of a broader effort to increase overall investments in health.29,81,82 
Increasing investment in infrastructure and health service deliv‐
ery (ie health systems strengthening) is not only a key enabler for 
viral hepatitis elimination but a requirement to reach the overarch‐
ing SDG 3 for health and its target of universal health coverage.19 
Ensuring that hepatitis services are integrated within these systems 
can reduce costs, compared to an isolated, non‐strategic approach,31 
exemplified here in the case of Rwanda.
Integrating the viral response into the health system by utilising 
existing structures and trained workforces can save costs and gener‐
ate efficiencies, as well as maximising access to services for key risk 
populations.83 For example conducting viral hepatitis testing at HIV 
services is likely to yield high diagnosis rates because people living 
with HIV have a higher risk of hepatitis B or hepatitis C co‐infection, 
and may improve their engagement in care.84 However, it is import‐
ant to look beyond integrating the response into HIV programmes, 
because further opportunities exist to broaden the viral hepatitis re‐
sponse by integrating it within tuberculosis, maternal and child health, 
and diabetes programmes. Also such an approach may not be useful 
in countries with generalised epidemics (such as China and Egypt) that 
require population‐based approaches to testing and treatment.
Even when the response is integrated within the broader health 
system, there will be extra costs due to the need to expand services 
and to increase staffing levels to accommodate the increased activ‐
ity. For example, additional time is needed to administer a hepatitis B 
vaccine or to provide post‐test counselling for positive test results.82 
Due to concerns about extra costs and workload, efforts to integrate 
viral hepatitis responses into existing systems and platforms may re‐
ceive substantial pushback, particularly initially. However, there is no 
evidence to support the notion that introducing viral hepatitis care 
into these systems causes existing structures to collapse.85
Moreover, multiple countries have been able to make treatment 
accessible to the broader population by successfully negotiating 
with patent holders (eg Australia), making use of patent licenses ei‐
ther available directly from the patent owner or those held by the 
Medicines Patent Pool (eg Rwanda),86 or using TRIPS flexibilities to 
circumvent patent barriers to accessing lower priced generic DAAs 
(eg Malaysia, see Table 4 and Appendix S1).87
Below are examples of integration: health systems strengthening 
(Rwanda) and investment and financing for sustainability (Australia). 
Importantly, the health systems in both countries have coped with 
this considerable scale‐up of treatment and care.
1.11 | Rwanda: expanding on universal 
health coverage
Rwanda is a low‐income country that is using a public health frame‐
work for hepatitis control and care to progress on its aim to achieve 
universal health coverage.
The country has made tremendous gains in maternal and child 
health, malaria, tuberculosis and HIV outcomes. The Rwandan 
Government now invests major resources in viral hepatitis, using 
programmatic steps that form a blueprint for other low‐income 
countries in the region.88 Key elements of Rwanda's programme for 
viral hepatitis prevention and treatment include:
• Simplified treatment algorithms not requiring hepatitis C geno‐
type or hepatitis B viral load and largely able to be delivered by 
nurses at health centre level
• Selective partnerships and preferred suppliers to drive down 
price, consolidate the supply chain and streamline diagnostic plat‐
forms to avoid siloed approaches to healthcare89
• Study of necessary resources for efficient implementation
• Development of a training programme for health staff
• Development, funding and implementation of birth dose vaccina‐
tion for hepatitis B.
To ascertain feasibility and ensure financing for sustainability, a national 
operational plan was developed to demonstrate priority‐setting of key 
activities and provide costing estimates for different levels of coverage of 
screening, diagnosis, and treatment of both hepatitis B and C.88 Several 
initiatives were used to secure funding, including support from interna‐
tional donors, in particular the Clinton Health Access Initiative. Rwanda 
has a voluntary licensing agreement for DAAs and is therefore able to 
produce medication at reduced cost (approx. US$ 560 in 2017).66,88 
Rwanda's Essential Medicines List includes generic hepatitis B medicines 
treatment; this is subsidised by government for people with HIV coin‐
fection. All major private health insurance companies (as well as military 
medical insurance) reimburse for the cost of DAAs, and the Rwanda social 
security board covers 85% of the cost. Ultimately, the aim is to provide 
reimbursement for hepatitis C diagnostics and treatment by the commu‐
nity‐based health insurance scheme.88 As of June 2017, 2500 patients 
had been treated with DAAs and treatment for 9000 additional patients 
had been procured (Figure 7A). Rwanda aims to establish treatment ca‐
pacity at all 48 district hospitals countrywide by 2020.
Major ongoing barriers to addressing viral hepatitis in Rwanda 
include the lower awareness of, and priority given to, viral hepati‐
tis compared to other infectious diseases (eg malaria and HIV) and 
the competing priorities for limited public‐sector health funding. A 
prior strategy (from 2011) that failed and has since been abandoned 
was to develop local viral hepatitis treatment guidelines based upon 
international consensus guidelines, without sufficient attention to 
the resources required for implementation (including particularly 
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laboratory testing and availability of medications) or the skills and 
experience required of clinicians. These guidelines thus lacked local 
contextualisation and recommended unavailable or unaffordable 
management; consequently, they were impractical and did not influ‐
ence daily clinical practice greatly.
1.12 | Australia: a multipronged approach to 
elimination
In 1999, Australia was one of the first countries to implement and 
subsequently refine their national hepatitis C strategies and has 
since then become a best practice model for hepatitis C elimination. 
Key to Australia's response, including achieving universal treatment 
access (described below), has been strong community advocacy, 
health research, health sector and political leadership that foster 
continued commitment to the WHO 2030 elimination targets, in‐
cluding a timely response to new challenges.90 Australia has had a 
long and sustained harm reduction approach to injecting drug use, 
with engagement of civil society, the health sector and government. 
This is beneficial in reducing bloodborne virus transmission and cul‐
tivates a point of engagement with PWID in providing health and 
social services.59‐61,91 Strong engagement with PWID is crucial to 
Australia's response.
By negotiating a volume‐based, risk‐sharing agreement with 
originator pharmaceutical companies and committing over AUD1 
billion to the purchase of DAAs between March 2016 and February 
2021, Australia obtained major discounts on drug list prices and as 
a consequence limited its expenditure. With no cap on treatment 
numbers,92 there is an incentive to diagnose and treat as many peo‐
ple as possible to maximise Australia's investment and its public 
health benefits. This provides an enabling environment to prioritise 
high‐prevalence groups with ongoing risks for treatment, such as 
PWID and prisoners, necessary to achieve hepatitis C elimination. 
In addition, all registered medical practitioners are able to prescribe 
DAA therapy, enabling more convenient, patient‐centred care. In 
Australia, close collaboration between people living with hepatitis 
C, community organisations, clinicians and policymakers facilitated 
improved access to diagnosis and treatment scale‐up (Figure 7B).
Australia aims to treat around 15 000 to 20 000 hepatitis C pa‐
tients per year, to reach the WHO target to eliminate viral hepati‐
tis as a major public health threat by 2030. This early commitment 
to achieving elimination and provide unrestricted treatment access 
enabled rapid treatment uptake during the first two years of DAA 
availability.90 Between March 2016 and late 2018, over 70 000 pa‐
tients (around 30% of all infected Australians) were treated. The 
proportion of individuals prescribed DAA treatment by general 
practitioners increased from 8% in March 2016 to 39% in June 
2017.93 With the successful implementation of its hepatitis C strat‐
egy – a global benchmark for best practice94 – Australia is on track 
to achieve elimination by 2030.95
Of concern in Australia is the continuing drop off in the num‐
ber of patients undergoing screening and confirmatory testing and 
treatment since March 2016.93 While treatment numbers have been 
sufficient to maintain the elimination targets, further decline could 
F I G U R E  7   Timeline of national activities, Rwanda (A) and Australia (B)
(A)
(B)
1832  |     SCHRÖEDER Et al.
put the elimination effort at risk. The decline in treatment numbers 
demonstrates that universal availability of DAA treatment alone is 
not enough to improve access to diagnosis and retention in care. 
Continued political commitment and policy and health system in‐
terventions are needed to facilitate treatment access for key pop‐
ulations to sustain momentum and overcome ongoing programme 
challenges to treatment scale‐up.
2  | DISCUSSION
The broader benefits of investing in the elimination of viral hepa‐
titis – including progressing on the SDGs ‐ are increasingly being 
recognised. Countries with different income levels, public health in‐
frastructures and policy environments are effectively responding to 
their respective epidemics.
Attaining the viral hepatitis elimination targets set by the global 
community in 2016 is achievable but also highly ambitious and comes 
with considerable challenges (see Appendix S1). These should not be 
ignored, but instead considered and addressed both at a global level 
and within the local context to invigorate and maintain national elim‐
ination efforts. Gathering sufficient funds to finance viral hepatitis 
programmes continues to be difficult among competing health prior‐
ities and budget constraints. Not all countries currently benefit from 
generic competition, with heavily burdened middle‐income countries 
(eg China, Malaysia, Thailand) struggling to afford higher drug prices. 
A further obstacle is the increasing cost of diagnostics; for example, 
in Egypt expenditure on diagnostics now exceeds that on hepatitis 
C treatment.68 There are few WHO prequalified point‐of‐care viral 
hepatitis tests and little production of low‐cost high‐quality generic 
tests. In many low‐income countries, strengthening primary health 
care systems for maternal and child health, developing laboratory ca‐
pacity, and improving weak registration and procurement systems for 
essential medicines is an ongoing challenge. For hepatitis B, cold chain 
barriers to vaccination including birth dose delivery exist, and while 
the controlled temperature chain presents a cost‐effective alternative 
that could vastly improve coverage96 it is yet to be broadly adopted.
Even in countries such as Australia, where there is close collab‐
oration between community, government and health practitioners 
to guide implementation, elimination cannot be guaranteed because 
many patients remain undiagnosed and/or do not access treat‐
ment.93,97,98 Identification of sufficient numbers of infected patients 
needing treatment remains a challenge globally; meanwhile, in coun‐
tries where scale‐up of a viral hepatitis response is pending, demand 
for viral hepatitis testing and treatment can outstrip available testing 
and treatment facilities,85 creating bottlenecks within the care cas‐
cade leading to losses to follow‐up. High levels of stigma, discrimi‐
nation, social marginalisation and legal impediments imposed on key 
populations at risk or infected with viral hepatitis (eg PWID, prisoners, 
men who have sex with men, sex workers) is a major issue preventing 
engagement in care and service access84 and in many countries legal 
protections remain insufficient.68 The impact of regressive policies 
and laws on the elimination response cannot be underestimated.
The country case studies presented here demonstrate that major 
gains are possible in spite of these challenges – across various epi‐
demic profiles, within a diverse range of resource constraints and 
within relatively short‐time frames. The case studies illustrate that 
political will and commitment, civil society advocacy, donor support 
and community acceptance are crucial and can make a difference. 
From concerted screening efforts in Egypt and using innovative ap‐
proaches to increase hepatitis C testing in Scotland, to building local 
investment cases in South Africa, to integrating viral hepatitis ser‐
vices into existing health infrastructure in Brazil and Rwanda, these 
pioneers provide important models for other countries to follow. In 
all countries multi‐stakeholder engagement of national and interna‐
tional experts, civil society organisations and affected communities 
form critical components across the three pillars of evidence‐gath‐
ering and planning, implementation and integration.
On a global level, civil society bodies such as the World Hepatitis 
Alliance are instrumental in generating pressure on governments 
and international organisations, providing an evidence‐based ap‐
proach to the response.82 Locally, robust evidence and civil society 
advocacy helped to achieve political commitment and facilitated 
the development of national plans. Collaboration and cooperation 
between civil society, the pharmaceutical industry and government 
smoothed the introduction of prevention and control programmes. 
Such unified, evidence‐informed strategies at the political and tech‐
nical levels are crucial to attract and sustain commitment and financ‐
ing. Learnings from these country examples and other local projects 
demonstrating the feasibility of elimination (eg micro‐elimination 
projects36,99) can help persuade policymakers in other countries to 
support viral hepatitis prevention and control plans. In‐country and 
global advocacy must be maintained to keep viral hepatitis high on 
the political agenda.82
3  | CONCLUSION
At the 2016 World Health Assembly, the global community 
uniformly endorsed the unique opportunity to eliminate viral 
hepatitis as a public health threat. Although an ambitious goal, 
technological advancements have made it scientifically feasible 
and increasing recognition of the public health threat posed by 
viral hepatitis provides the grounds for substantial political and 
societal support. The broader benefits of investing in the elimi‐
nation of viral hepatitis – including progress on the Agenda for 
Sustainable Development – are now well recognised. Sustaining 
political momentum will be critical if elimination efforts are to be 
successful and more countries will need to take action if global 
elimination of viral hepatitis is to be achieved. Looking to exist‐
ing approaches that address viral hepatitis can facilitate political 
support, because they demonstrate that investing in viral hepati‐
tis is cost‐effective and can be made affordable, provide multiple 
economic benefits, and above all alleviate the human burden of 
the epidemic. The case studies presented in this paper provide 
clear and feasible examples of successful approaches taken by 
     |  1833SCHRÖEDER Et al.
low‐, middle‐ and high‐income countries with diverse epidemics of 
hepatitis B and C to achieve the WHO 2030 viral hepatitis elimina‐
tion targets.
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